Multikinase inhibitors and uses in reproductive and digestive tract fibrosis
US11400089B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Aug 13, 2018 |
| Grant date | Aug 2, 2022 |
| Priority date | — |
| Expiry date | Mar 2, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P17/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for preventing and/or treating fibrosis associated with a reproductive tract or digestive tract disease or disorder includes administering an effective amount of a multikinase inhibitor to an animal or human in need thereof. The multikinase inhibitor comprises axitinib, nintedanib, sunitinib, lenvatinib, regorafenib, ponatinib, pazopanib, riociguat, or a salt thereof. The reproductive tract or digestive tract disease or disorder comprises uterine fibroids or primary sclerosing cholangitis, including Intra uterine surgery, intra uterine synechiae, Asherman's syndrome, biliary duct fibrosis, biliary duct sclerosis, and primary biliary cirrhosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.